Valuation: Kadimastem

Market Cap 55.03M 5.5B 17.98M 16.06M 14.93M 13.57M 25.61M 1.74B 25.76M 180M 70.29M 886M 67.53M 66.05M 2.85B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 55.03M 5.5B 17.98M 16.06M 14.93M 13.57M 25.61M 1.74B 25.76M 180M 70.29M 886M 67.53M 66.05M 2.85B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
34.42%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-8.93% - - 17.96M
-2.59%-5.70%+40.86%+83.11% 72.13B
+3.23%-13.45%+6.00%+55.77% 49.41B
+1.56%+2.07%+5.03%+33.38% 47.24B
+0.87%-7.83%+296.82%+657.83% 40.32B
+0.39%-0.32%+29.55%+30.83% 42.61B
+1.24%-1.20%+0.96%+103.86% 39.81B
-2.13%-2.18%+7.51%+50.31% 30.52B
+5.32%+0.11%-8.77%-12.81% 23.13B
+3.78%+5.71%+16.43%-1.77% 21.09B
Average +1.17%-3.91%+43.82%+111.17% 40.7B
Weighted average by Cap. +0.78%-4.28%+46.74%+118.77%

Financials

2026 *2027 *
Net sales - -
Net income - -
Net Debt - -
Logo Kadimastem
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
Employees
11